Chara Stavraka

NIHR Clinical Lecturer

King’s College London

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Chara Stavraka is a NIHR Clinical Lecturer at King's College London, United Kingdom. Her research primarily focuses on the development and evaluation of IgE antibodies for cancer therapy, with recent articles addressing non-allergic skin reactions, macrophage interactions in ovarian cancer, and the clinical significance of basophils in cancer patients. She is also involved in assessing the prognostic value of KRAS mutations in metastatic colorectal cancer.

Articles (14)

Year:

2025

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (16)

Philip Blower

King’s College London

UNITED KINGDOM

Chara Stavraka

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

Non-Allergic Urticarial Skin Reactions Associated With MOv18 IgE, a First-In-Class IgE Antibody Recognising Folate Receptor Alpha

Hyperinflammatory repolarisation of ovarian cancer patient macrophages by anti-tumour IgE antibody, MOv18, restricts an immunosuppressive macrophage:Treg cell interaction

Physiochemical and functional evaluation of the first-in-class anti-cancer IgE antibody drug, MOv18, through process development and good manufacturing practice production

Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha

Anti-cancer Pro-inflammatory Effects of an IgE Antibody Targeting the Melanoma-associated Antigen Chondroitin Sulfate Proteoglycan 4

Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.

Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4.

Non-Small Cell Lung Cancer (NSCLC) in Young Adults, Age < 50, Is Associated with Late Stage at Presentation and a Very Poor Prognosis in Patients That Do Not Have a Targeted Therapy Option: A Real-World Study

Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes

Clinical and Translational Significance of Basophils in Patients with Cancer

Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.

Insights from IgE immune surveillance in allergy and cancer for anti-tumour IgE treatments

Trifluridine/Tipiracil in Metastatic Colorectal Cancer: A UK Multicenter Real-world Analysis on Efficacy, Safety, Predictive and Prognostic Factors

The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer

Collaborators (16)

Philip Blower

Panagiotis Karagiannis

Alicia Michelle Chenoweth

Udai Banerji

David J. Pinato

Mariangela Figini

Rebecca S. Kristeleit

James Arnold

Alessio Cortellini

Chris Corrigan

Nicla La Verde

Jitesh Chauhan

Sophia Karagiannis

Heather J. Bax

James Spicer

Gary Cook

Make your next move.